news
B-ALL: combination therapy effectively controls high-risk subtypes
The combination therapy worked faster and was lessened the number of leukaemia cells compared to asparaginase or venetoclax alone.
List view / Grid view
St Jude Children’s Research Hospital
news
Reversing malignant cancer cells to a normal state
A new proof-of-principle study demonstrates the DCAF5 protein is a promising target, which could avoid the need for toxic therapies.
news
The first core regulatory circuit identified for ALCL
New understanding of the CRC and its interaction with STAT3 could lead to novel therapeutics and combination strategies.
news
Improved CAR T-cell immunotherapy for acute myeloid leukaemia
Researchers have created dual-targeted CARs, which performed better than single-targeted CARs in both in vivo and in vitro experiments.
news
RBM5: potential drug target for acute myeloid leukaemia
RBM5 removal from cells meant that HOXA9 mRNA levels were greatly reduced, which could lead to therapies targeting HOXA9-driven leukaemia.
news
SCID-X1 gene therapy successful with 3D genome architecture
New research improves patient care by finding where gene copies integrate into DNA and using lentiviral vectors.
news
Childhood cancer survivors’ mortality risk
Researchers find genetic explanation for increased risk of developing second cancers.
news
Immune cells predict flu symptoms
St. Jude Children’s Research Hospital, in collaboration with ESR Limited, discovered that specific immune cells present in individuals months before a flu infection can better predict symptom development compared to current antibody-based methods.
news
Cracking the code of influenza evolution
Researchers provide new insights into viral evolution and have significant implications for understanding and predicting the behaviour of influenza and other mutating diseases.
news
Computational tool gets more out of multi-omics data
US researchers developed a next-generation computational tool called NetBID2 that can uncover difficult-to-identify proteins that drive biological processes contributing to cancer.
news
Combination therapy prevails against BET inhibitor resistance
St. Jude Children's Research Hospital, US, scientists created a new combination therapy method to tackle drug resistance in a type of leukaemia with KMT2A gene rearrangement.
news
Concerns for future gene therapy testing in laboratory mice
Researchers have found that new sickle cell disease gene therapies depend on choosing the right laboratory mice.
news
Controlling PTEN gene could combat paediatric rhabdomyosarcoma
The decreased expression of PTEN in mouse models was found to make rhabdomyosarcoma tumours more aggressive, highlighting new treatment approaches.
news
Metabolic pathway could potentially enhance vaccine effectiveness
A metabolic control pathway that regulates T follicular helper cells could enhance vaccine effectiveness, including those that protect against COVID-19.
news
Blocking Treg pathway sensitises mice to immunotherapy
Researchers have shown that inhibiting Treg activation in tumours can provide effective immune responses without autoimmune toxicity.